TriangleHEALTH PROFESSIONAL · SOURCE READING
Vandetanib
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Vandetanib is an oral inhibitor of rearranged during transfection (RET) receptor kinase, vascular endothelial growth factor receptor (VEGFR), and epidermal growth-factor receptor.
Evidence (vandetanib):
A placebo-controlled prospective trial (NCT00410761) evaluated vandetanib in 331 patients with locally advanced or metastatic disease. Patients were randomly assigned in a 2:1 ratio to receive vandetanib or placebo.[11][Level of evidence B1]
Source links and citations
A placebo-controlled prospective trial (NCT00410761) evaluated vandetanib in 331 patients with locally advanced or metastatic disease. Patients were randomly assigned in a 2:1 ratio to receive vandetanib or placebo.[11][Level of evidence B1]
With a median follow-up of 24 months, progression-free survival (PFS) favored vandetanib (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.31–0.69; P < .001), with a median PFS estimated at 30.5 months for vandetanib versus 19.3 months for placebo.
A placebo-controlled prospective trial (NCT00410761) evaluated vandetanib in 331 patients with locally advanced or metastatic disease. Patients were randomly assigned in a 2:1 ratio to receive vandetanib or placebo.[11][Level of evidence B1]
OS was not different at 24 months. Longer follow-up will be required because all but 47 patients were alive at the time of analysis, and there was a crossover to the study drug on progression from placebo, making analysis of OS problematic.
A placebo-controlled prospective trial (NCT00410761) evaluated vandetanib in 331 patients with locally advanced or metastatic disease. Patients were randomly assigned in a 2:1 ratio to receive vandetanib or placebo.[11][Level of evidence B1]
Vandetanib treatment produces significant side effects, including diarrhea, rash, hypertension, and QT prolongation. Quality of life was not formally assessed in this trial.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice